Article
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
Liver international : official journal of the International Association for the Study of the Liver - 1 Aug 2020
Abergel Armand, Asselah Tarik, Mallat Arianne, Chanteranne Brigitte, Faure Frederic, Larrey Dominique, Gournay Jerome, Loustaud-Ratti Veronique, Di Martino Vincent, Fouchard-Hubert Isabelle, Pol Stanislas, Bailly Francois, Samuel Didier, Tran Albert, Dodel Marie, Andant Nicolas, Lamblin Geraldine, Muti Leon, Reymond Maud, Teilhet Camille, Pereira Bruno, Buchard Benjamin
Abstract excerpt
BACKGROUND: Genotype 1b is the most common HCV genotype worldwide, accounting for the largest proportion of infections in Europe, Russia, Latin America and Asia. Reducing treatment duration can improve adherence, reduce drug exposure and cost. Accordingly, we evaluated the efficacy of 8 weeks fixed-dose combination of grazoprevir-elbasvir in treatment-naïve patients, with non-severe fibrosis. METHODS: HCV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.